DKNG vs GENI: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

DKNG is the larger of the two ($9.21B market cap): the incumbent the market prices for continued execution (13.00x forward earnings, beta 1.61). GENI is the smaller challenger ($1.66B), cheaper on forward earnings (5.83x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

DKNG vs GENI: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDKNGGENIWhat it tells you
Market cap$9.21B$1.66BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E13.005.83Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.611.88Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range9% of range30% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book51.222.42How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: GENI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how DKNG and GENI affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DKNG and GENI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DKNG and GENI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does DraftKings (DKNG) do?

DraftKings operates one of the largest US online sports betting (OSB) and iGaming platforms, alongside a daily fantasy sports business, a former retail-lottery courier operation, and a growing prediction-markets product (Pick6). Revenue comes primarily from the Sportsbook (hold on wagering handle) and iGaming (online casino), with the company live in dozens of US states plus Ontario. It sits in a consolidated duopoly with FanDuel (Flutter), with the two names controlling roughly three-quarters or more of US gross gaming revenue.

Full DKNG guide

What does Genius Sports (GENI) do?

Genius Sports Limited is a sports data and technology company incorporated in Guernsey, headquartered in London, and listed on the New York Stock Exchange since its 2021 SPAC combination. The model has three linked parts. It signs exclusive rights with leagues and federations to collect their official real-time data, it distributes that data plus trading and streaming products to regulated sportsbooks, and it supplies technology back to the leagues themselves, which is often how the rights get paid for. Its anchor asset is the NFL, where Genius is the exclusive distributor of official data feeds and operates BetVision, the low-latency watch-and-bet product embedded inside sportsbook apps. That partnership was extended and widened and now runs through the end of the 2029 NFL season, and it lets Genius monetise advertising inventory against the BetVision streams; in October 2026 Genius also began feeding official real-time NFL data to NFL Gametime on X. Beyond the NFL, the rights portfolio spans several hundred competitions including English football and FIBA basketball.

Full GENI guide

DKNG vs GENI: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • DKNG drivers: Duopoly scale and structural profitability; New-state and iGaming expansion.
  • GENI drivers: The NFL contract and BetVision; Legend and the pivot into owned media.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Profitability is now the central risk: GAAP results are back in loss territory over the trailing twelve months, Q2 2026 missed EPS estimates by half, and analysts expect a loss of about $0.17 per share in Q3 as prediction-market and marketing spending rise. For GENI, the dominant structural risk is rights renewal: Genius does not own the sports, it rents them, and every renewal is an auction that Sportradar and others can bid up until the contract stops being profitable.

DKNG or GENI: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DKNG if you believe its drivers more; GENI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DKNG and GENI guides.

DKNG vs GENI: the full fundamentals

DKNG. DraftKings is valued on scale and future profitability rather than current earnings, and with trailing GAAP results back to a loss, the trailing P/E is not meaningful. The stock now trades near 1.5x sales and about 11x 2027 consensus EPS, far cheaper than in July, because the market doubts how fast revenue growth (consensus 2026 revenue ~$6.7 billion) converts into margin while prediction-market and marketing costs rise. The 36 analysts Yahoo Finance tracks have a mean target near $34. Guidance, hold and prediction-market spending tend to move the stock more than reported net income.

GENI. At roughly $1.72 billion the market cap is about 2.2x trailing revenue and roughly 1.7x the midpoint of guided 2026 revenue, or about 6x guided adjusted EBITDA before adding the roughly $666 million of net debt, which lifts the enterprise value multiple to around 8x. That is a far lower multiple than in August, when the shares were near $8.38, and it is still being paid on an adjusted figure while GAAP results are loss-making. Analysts tracked by Yahoo have a mean target near $10.83. Figures are approximate and tied to the asOf date, so check live numbers and the latest 6-K before drawing conclusions.

Headline figures (approximate, October 2026): DKNG shows revenue (ttm) ~$6.2 billion, q2 2026 revenue ~$1.44 billion (down ~4.6% YoY), eps Q2 2026 adjusted $0.09 vs $0.19 estimate; 2026 consensus ~$0.88, 2027 ~$1.70, net income (ttm) ~-$167 million (GAAP loss); GENI shows revenue (ttm) ~$790 million, q2 2026 revenue ~$196 million, up ~65% year over year and ahead of ~$185 million guided; adjusted EPS $0.07 vs $0.04 expected, q2 2026 adjusted ebitda ~$53 million against ~$45 million guided, fy2026 guidance (reaffirmed sep 28, 2026) ~$1.005 billion to ~$1.025 billion revenue, ~$285 million to ~$295 million adjusted EBITDA (~28.6% margin at midpoint).

The bottom line: DKNG vs GENI

DKNG and GENI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DKNG and GENI exposure against your real portfolio. It is not an investment adviser.

Wondering how DKNG or GENI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about DraftKings

Ask Walnut's AI anything about DKNG and see how it fits what you own.

FAQ

What is the difference between DKNG and GENI?

+

DraftKings operates one of the largest US online sports betting (OSB) and iGaming platforms, alongside a daily fantasy sports business, a former retail-lottery courier operation, and a growing prediction-markets product (Pick6). Genius Sports Limited is a sports data and technology company incorporated in Guernsey, headquartered in London, and listed on the New York Stock Exchange since its 2021 SPAC combination. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DKNG or GENI the better stock?

+

Neither is universally better. DKNG is the larger incumbent; GENI is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DKNG or GENI?

+

On forward P/E (as of November 2026), DKNG trades at 13.00x and GENI at 5.83x, so GENI is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DKNG and GENI?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DKNG vs GENI?

+

DKNG: Profitability is now the central risk: GAAP results are back in loss territory over the trailing twelve months, Q2 2026 missed EPS estimates by half, and analysts expect a loss of about $0.17 per share in Q3 as prediction-market and marketing spending rise. Fanatics, Hard Rock and Bet365 are stepping up advertising, raising the chance of a costly promotional war. State tax increases (such as higher rates in Illinois, New Jersey, and elsewhere) directly compress unit economics. CFTC-regulated prediction markets like Kalshi and Polymarket can offer sports-style event contracts even in states where sportsbooks are banned (for example California), pressuring both the growth story and states' willingness to expand licensed betting; Jefferies sees possible regulatory action against them by summer 2027. Results also swing with sport outcomes, and the stock is volatile, down about 47% in 2026. GENI: The dominant structural risk is rights renewal: Genius does not own the sports, it rents them, and every renewal is an auction that Sportradar and others can bid up until the contract stops being profitable. Customer concentration compounds it, because a handful of large sportsbooks generate a substantial share of Betting revenue and any one of them insourcing trading or data would be difficult to replace. Reported profitability remains negative, with a trailing net loss near $182 million and a second-quarter 2026 loss of about $77 million, so the equity story currently rests on adjusted EBITDA, a measure that excludes share-based compensation and acquisition costs. The Legend deal added about $821 million of debt on the balance sheet, contingent consideration tied to performance targets and integration work, and its affiliate sites depend on search traffic that a Google algorithm change can reduce without warning. The share count has also grown, and short interest has been elevated. The roughly 40% fall in the stock during 2026 shows how much the market discounts these risks. Regulatory shifts such as Brazil's September 2026 ban on fixed-odds betting, higher betting taxes on operators, and the growth of prediction-market exchanges that sit outside the traditional sportsbook customer base are all outside the company's control.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DKNG or GENI; figures are approximate and dated (as of November 2026). Verify current data before investing.